Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078]

Detalles Bibliográficos
Autores principales: Banna, G.L., Cortellini, A., Cortinovis, D.L., Tiseo, M., Aerts, J.G.J.V., Barbieri, F., Giusti, R., Bria, E., Grossi, F., Pizzutilo, P., Berardi, R., Morabito, A., Genova, C., Mazzoni, F., Di Noia, V., Signorelli, D., Gelibter, A., Macerelli, M., Rastelli, F., Chiari, R., Rocco, D., Gori, S., De Tursi, M., Di Marino, P., Mansueto, G., Zoratto, F., Filetti, M., Montrone, M., Citarella, F., Marco, R., Cantini, L., Nigro, O., D'Argento, E., Buti, S., Minuti, G., Landi, L., Guaitoli, G., Lo Russo, G., De Toma, A., Donisi, C., Friedlaender, A., De Giglio, A., Metro, G., Porzio, G., Ficorella, C., Addeo, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Corrigendum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233644/
https://www.ncbi.nlm.nih.gov/pubmed/34144775
http://dx.doi.org/10.1016/j.esmoop.2021.100137
_version_ 1783713899538808832
author Banna, G.L.
Cortellini, A.
Cortinovis, D.L.
Tiseo, M.
Aerts, J.G.J.V.
Barbieri, F.
Giusti, R.
Bria, E.
Grossi, F.
Pizzutilo, P.
Berardi, R.
Morabito, A.
Genova, C.
Mazzoni, F.
Di Noia, V.
Signorelli, D.
Gelibter, A.
Macerelli, M.
Rastelli, F.
Chiari, R.
Rocco, D.
Gori, S.
De Tursi, M.
Di Marino, P.
Mansueto, G.
Zoratto, F.
Filetti, M.
Montrone, M.
Citarella, F.
Marco, R.
Cantini, L.
Nigro, O.
D'Argento, E.
Buti, S.
Minuti, G.
Landi, L.
Guaitoli, G.
Lo Russo, G.
De Toma, A.
Donisi, C.
Friedlaender, A.
De Giglio, A.
Metro, G.
Porzio, G.
Ficorella, C.
Addeo, A.
author_facet Banna, G.L.
Cortellini, A.
Cortinovis, D.L.
Tiseo, M.
Aerts, J.G.J.V.
Barbieri, F.
Giusti, R.
Bria, E.
Grossi, F.
Pizzutilo, P.
Berardi, R.
Morabito, A.
Genova, C.
Mazzoni, F.
Di Noia, V.
Signorelli, D.
Gelibter, A.
Macerelli, M.
Rastelli, F.
Chiari, R.
Rocco, D.
Gori, S.
De Tursi, M.
Di Marino, P.
Mansueto, G.
Zoratto, F.
Filetti, M.
Montrone, M.
Citarella, F.
Marco, R.
Cantini, L.
Nigro, O.
D'Argento, E.
Buti, S.
Minuti, G.
Landi, L.
Guaitoli, G.
Lo Russo, G.
De Toma, A.
Donisi, C.
Friedlaender, A.
De Giglio, A.
Metro, G.
Porzio, G.
Ficorella, C.
Addeo, A.
author_sort Banna, G.L.
collection PubMed
description
format Online
Article
Text
id pubmed-8233644
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-82336442021-06-29 Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078] Banna, G.L. Cortellini, A. Cortinovis, D.L. Tiseo, M. Aerts, J.G.J.V. Barbieri, F. Giusti, R. Bria, E. Grossi, F. Pizzutilo, P. Berardi, R. Morabito, A. Genova, C. Mazzoni, F. Di Noia, V. Signorelli, D. Gelibter, A. Macerelli, M. Rastelli, F. Chiari, R. Rocco, D. Gori, S. De Tursi, M. Di Marino, P. Mansueto, G. Zoratto, F. Filetti, M. Montrone, M. Citarella, F. Marco, R. Cantini, L. Nigro, O. D'Argento, E. Buti, S. Minuti, G. Landi, L. Guaitoli, G. Lo Russo, G. De Toma, A. Donisi, C. Friedlaender, A. De Giglio, A. Metro, G. Porzio, G. Ficorella, C. Addeo, A. ESMO Open Corrigendum Elsevier 2021-06-03 /pmc/articles/PMC8233644/ /pubmed/34144775 http://dx.doi.org/10.1016/j.esmoop.2021.100137 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Corrigendum
Banna, G.L.
Cortellini, A.
Cortinovis, D.L.
Tiseo, M.
Aerts, J.G.J.V.
Barbieri, F.
Giusti, R.
Bria, E.
Grossi, F.
Pizzutilo, P.
Berardi, R.
Morabito, A.
Genova, C.
Mazzoni, F.
Di Noia, V.
Signorelli, D.
Gelibter, A.
Macerelli, M.
Rastelli, F.
Chiari, R.
Rocco, D.
Gori, S.
De Tursi, M.
Di Marino, P.
Mansueto, G.
Zoratto, F.
Filetti, M.
Montrone, M.
Citarella, F.
Marco, R.
Cantini, L.
Nigro, O.
D'Argento, E.
Buti, S.
Minuti, G.
Landi, L.
Guaitoli, G.
Lo Russo, G.
De Toma, A.
Donisi, C.
Friedlaender, A.
De Giglio, A.
Metro, G.
Porzio, G.
Ficorella, C.
Addeo, A.
Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078]
title Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078]
title_full Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078]
title_fullStr Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078]
title_full_unstemmed Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078]
title_short Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078]
title_sort corrigendum to ‘the lung immuno-oncology prognostic score (lips-3): a prognostic classification of patients receiving first-line pembrolizumab for pd-l1 ≥ 50% advanced non-small-cell lung cancer’: [esmo open volume 6, issue 2, april 2021, 100078]
topic Corrigendum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233644/
https://www.ncbi.nlm.nih.gov/pubmed/34144775
http://dx.doi.org/10.1016/j.esmoop.2021.100137
work_keys_str_mv AT bannagl corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT cortellinia corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT cortinovisdl corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT tiseom corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT aertsjgjv corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT barbierif corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT giustir corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT briae corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT grossif corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT pizzutilop corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT berardir corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT morabitoa corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT genovac corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT mazzonif corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT dinoiav corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT signorellid corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT gelibtera corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT macerellim corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT rastellif corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT chiarir corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT roccod corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT goris corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT detursim corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT dimarinop corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT mansuetog corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT zorattof corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT filettim corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT montronem corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT citarellaf corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT marcor corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT cantinil corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT nigroo corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT dargentoe corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT butis corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT minutig corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT landil corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT guaitolig corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT lorussog corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT detomaa corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT donisic corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT friedlaendera corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT degiglioa corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT metrog corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT porziog corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT ficorellac corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078
AT addeoa corrigendumtothelungimmunooncologyprognosticscorelips3aprognosticclassificationofpatientsreceivingfirstlinepembrolizumabforpdl150advancednonsmallcelllungcanceresmoopenvolume6issue2april2021100078

Ejemplares similares